CRC, such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA199), and tumor-specific growth factor. Nevertheless, their clinical effectiveness for CRC early detection remains controversial. 4 It has been widely known that cancers are closely associated with systemic inflammatory response and the nutritional status of patients. Plenty of evidence indicated that inflammation plays a vital role in the development and progression of various cancers, including CRC. [5] [6] [7] Meanwhile, malnutrition is a significant problem in cancer patients and could result in a number of clinical consequences, such as deteriorated quality of life, decreased response to treatment, and shorter survival rate. 8 Accordingly, some novel biomarkers which reflected the systemic inflammation and nutritional status were increasingly investigated in the prediction of cancer progression and prognosis, such as neutrophil-to-lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and the modified Glasgow prognostic score (mGPS). 9, 10 However, there were few studies to report the diagnostic value of these inflammation-based biomarkers.
Fibrinogen (Fib), which plays a vital part in clot formation, was also observed to act as a prominent role in directly or indirectly regulating inflammatory response. 11, 12 Many studies have emphasized that the preoperative plasma Fib level could independently predict prognosis of various cancers. [13] [14] [15] [16] [17] Furthermore, serum albumin (Alb)
or pre-albumin (pAlb) level was proved to be significant low in cancer individuals comparing to healthy controls. 18, 19 Hence, Fib-to-Alb ratio (FAR, 100*Fib/Alb) and Fib-to-pAlb ratio (FPR, Fib/pAlb), which could reflect both the inflammatory and nutritional state, seem to be potential diagnostic biomarkers for CRC patients.
In this study, we comprehensively analyzed the diagnostic value of FAR and FPR in CRC and explored whether biomarker combinations could improve the diagnostic efficacy in distinguishing CRC from the benign colorectal disease.
| MATERIAL S AND ME THODS

| Study population
According to the power (1−β = 0.85) and the level of significance (α < 0.05), the minimum sample size of the cases and controls was calculated as 403 using PASS version 11.0.10. Thus, a total of 455 CRC patients newly diagnosed at the Second Affiliated Hospital of Nanchang University between Jan 2011 and Dec 2014 were enrolled in our study. The cases were confirmed by two pathologists according to the American Joint Committee on Cancer TNM staging system (7th Edition) classification system. In addition, 455 patients with colorectal polyp were included as benign controls, and sex-and age-matched healthy individuals were enrolled as healthy controls.
Patients without hematological disorders, hepatic damage, autoimmune diseases, recent infection, or other malignancies were eligible for enrollment. Healthy controls were collected by physical examination, including the questionnaire, the blood routine examination, all blood biochemical indices, B-ultrasonography, and imagological examination. Ethical approval was obtained from the Second Affiliated
Hospital of Nanchang University and adhered to the tenets of the Declaration of Helsinki.
| Clinical parameter and laboratory results
Patients' clinical parameter including age, sex, tumor location, TNM classification, and tumor grade were retrieved from medical records.
Meanwhile, laboratory results were also collected from medical records. Clauss method was selected to detect circulating Fib using SYSMEX CA-7000 machine (Sysmex, Tokyo, Japan). Bromocresol green and immune turbidimetric methods were chosen to measure serum concentrations of Alb and pAlb using OLYMPUS AU5400 machine (Beckman Coulter, Tokyo, Japan). Electro-chemiluminescence immunoassay was used to detect serum levels of CEA and CA199
by the machine of SIEMENS ADVIA Centaur CP (Siemens, Erlangen, Germany). All peripheral blood, plasma, and serum samples were collected from 7:30 to 9:30 am in the period before the intervention.
And the respective inter-and intra-batch coefficient of variance of the kits was <5%.
| Statistical analysis
The minimum sample size was calculated by PASS version 11. 
| RE SULTS
| Clinical characteristics of enrolled participants
The overall baseline characteristics of all the participants were summarized in Table 1 . Four hundred and fifty-five CRC cases, 455 healthy controls, and 455 benign controls were recruited.
The median age of the CRC patients, healthy controls, and benign controls were 58, 55, and 57, respectively. There is no statistical significance between three groups in age (P > 0.05 TA B L E 1 The baseline characteristics of the CRC, healthy, and benign controls II and III/IV stage comparing to the controls, and the levels in stage III/IV exceed that in stage I/II patients for these three biomarkers (Figures 2 and S1B ).
| Diagnostic value of FPR, FAR, and NLR
Receiver-operating characteristics analysis showed that FAR owned the highest diagnostic efficacy in discriminating cases from healthy controls, and the AUC (0.741) was close to that of FPR (0.738).
The optimal cutoff values of FAR and FPR were 8.018 (sensitivity, Sen = 50.5%, specificity, Spe = 86.2%, positive predictive value (PPV) = 78.5%, negative predictive value (NPV) = 63.5%), and 15.360 (Sen = 54.1%, Spe = 81.3%, PPV = 75.4%, NPV = 63.6%), respectively. Otherwise, the optimal cutoff value, AUC, sensitivity, and specificity value of NLR were 2.217, 0.644, 51.2%, and 74.3%
( Figure 3A and Table 3 ).
| Logistic regression analysis
Logistic regression analysis was used to evaluate the risk factors for telling CRC apart from benign disease. The risk factors found to be markedly associated with differentiation of benign disease and CRC in the regression analysis included FPR (odds ratio, OR = 5.532; 95% confidence interval, 95% CI = 3.715-8.238, P < 0.05), NLR (OR = 1.423, 95% CI = 1.022-1.981, P < 0.05), CEA (OR = 5.882, 95% CI = 4.016-8.615, P < 0.05), and CA199 (OR = 1.782, 95% CI = 1.258-2.524, P < 0.05) ( Table 2 ).
| Distinguishing CRC from benign disease
In the cases and benign controls, the diagnostic value of FPR was better than FAR, NLR, CEA, and CA199 (P < 0.05), indicating FPR was the best one among these biomarkers for distinguishing CRC from benign disease. Therefore, FPR in conjunction with other biomarkers were further analyzed for combined detection. (Figure 4) As expected, the combined biomarkers resulted in enhanced di- Table 3 ).
| D ISCUSS I ON
Cancer-related inflammation has been recognized as a hallmark of tumorigenesis and progression. 20 Numerous studies reported that inflammatory bowel disease could trigger choric inflammation and increase the risk of CRC. 21 On the contrary, the continuous use of low-dose anti-inflammatory drugs such as aspirin or NSAIDs could reduce the risk of CRC. 22 The measurement of the systemic inflammatory response has been extensively analyzed; however, the diagnostic roles of FAR and FPR in CRC remained unclear. F I G U R E 4 Receiver-operating characteristics (ROC) curve of combined biomarkers compared with benign controls in colorectal cancer (CRC) platelets, and endothelial cells, but also regulate tumor cell proliferation and migration by interacting with multiple receptors of cancer cells. 25, 26 Consequently, enhanced tumor cell escaping and impaired immunologic surveillance directly result in the onset and progression of cancer.
On the other hand, the prevalence of malnutrition is high in patients with cancer. Moreover, the common inflammatory cytokines, interleukin-6, could suppress the synthesis of nutritional protein, leading to hypoproteinemia in cancer patient. 27 Serum Alb and pre-Alb, two accepted biomarkers to assess the nutritional condition, were recognized to be significant factors to predict recovery and survival of CRC cases in some studies. 28 Above all, it appears to be reasonable to explore the diagnostic efficacy of FPR and FAR for CRC, and that could be more convincible on account of the combined reflection of inflammation and malnutrition. However, some limitations in the current study should be addressed. The sample size in the current study was small, and our results need to be validated by prospective research in further research around the world.
| CON CLUS ION
Fibrinogen/pre-Albumin represents a useful CRC diagnostic biomarker, and the combination of FPR, CEA, and CA199 could significantly improve the diagnostic efficacy in discriminating CRC from the benign colorectal disease. Fibrinogen/pre-Albumin; NLR, neutrophil-to-lymphocyte ratio; NPV, negative predictive value; PPV, positive predictive value; Sen, sensitivity; Spe, specificity; YI, Youden's index.
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